HomeCompareSHWGY vs MAIN

SHWGY vs MAIN: Dividend Comparison 2026

SHWGY yields 5.48% · MAIN yields 6.91%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MAIN wins by $36.53M in total portfolio value
10 years
SHWGY
SHWGY
● Live price
5.48%
Share price
$2.19
Annual div
$0.12
5Y div CAGR
61.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.36M
Annual income
$4,929,425.46
Full SHWGY calculator →
MAIN
Main Street Capital Corporation
● Live price
6.91%
Share price
$52.96
Annual div
$3.66
5Y div CAGR
72.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$42.89M
Annual income
$35,818,348.00
Full MAIN calculator →

Portfolio growth — SHWGY vs MAIN

📍 MAIN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSHWGYMAIN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SHWGY + MAIN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SHWGY pays
MAIN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SHWGY
Annual income on $10K today (after 15% tax)
$465.75/yr
After 10yr DRIP, annual income (after tax)
$4,190,011.64/yr
MAIN
Annual income on $10K today (after 15% tax)
$587.42/yr
After 10yr DRIP, annual income (after tax)
$30,445,595.80/yr
At 15% tax rate, MAIN beats the other by $26,255,584.16/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SHWGY + MAIN for your $10,000?

SHWGY: 50%MAIN: 50%
100% MAIN50/50100% SHWGY
Portfolio after 10yr
$24.62M
Annual income
$20,373,886.73/yr
Blended yield
82.74%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MAIN right now

SHWGY
No analyst data
Altman Z
2.6
Piotroski
6/9
MAIN
Analyst Ratings
2
Buy
11
Hold
Consensus: Hold
Price Target
$65.25
+23.2% upside vs current
Range: $60.00 — $70.00
Altman Z
1.7
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SHWGY buys
0
MAIN buys
0
No recent congressional trades found for SHWGY or MAIN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSHWGYMAIN
Forward yield5.48%6.91%
Annual dividend / share$0.12$3.66
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR61.9%72.7%
Portfolio after 10y$6.36M$42.89M
Annual income after 10y$4,929,425.46$35,818,348.00
Total dividends collected$6.21M$41.85M
Payment frequencyquarterlymonthly
SectorStockBDC

Year-by-year: SHWGY vs MAIN ($10,000, DRIP)

YearSHWGY PortfolioSHWGY Income/yrMAIN PortfolioMAIN Income/yrGap
1← crossover$11,587$887.12$12,434$1,193.51$847.00MAIN
2$13,954$1,555.33$16,255$2,280.05$2.3KMAIN
3$17,764$2,833.97$22,851$4,580.08$5.1KMAIN
4$24,467$5,459.09$35,577$9,892.59$11.1KMAIN
5$37,556$11,376.65$63,653$23,664.70$26.1KMAIN
6$66,608$26,422.93$136,601$65,054.52$70.0KMAIN
7$142,178$70,907.01$368,044$214,504.02$225.9KMAIN
8$381,141$229,011.21$1,301,668$887,987.40$920.5KMAIN
9$1,336,733$928,911.89$6,288,483$4,825,407.47$4.95MMAIN
10$6,359,730$4,929,425.46$42,886,603$35,818,348.00$36.53MMAIN

SHWGY vs MAIN: Complete Analysis 2026

SHWGYStock

Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, and sale of single-use medical devices in the People's Republic of China. It operates through Medical Device Products, Orthopaedic Products, Interventional Products, Pharma Packaging Products, Blood Management Products, and Others segments. The company offers vascular and non-vascular access infusion devices, infusion sets, syringes, puncture needles, and specialized single-use clinical collection kits; wound sutures, wound healing dressings, and wound cleaning and nonvascular catheter supporting extracorporeal devices; and blood collection, storage, separation, and sterilization equipment. It also provides prefilled syringes and pre-filled flush syringes; blood collection and blood glucose testing devices; and general anesthesia consumables, local anesthesia consumables, anesthesia auxiliary consumables, ICU equipment, and open and minimally invasive surgical equipment. In addition, the company engages in the production and sale of orthopedic devices; tumor and blood vessel interventional instruments; implantation materials and artificial organs; medical PVC granules, plastic packing bags, and carton boxes; industrial automatic equipment and parts; molds; hemodialysis equipment; and type I, type II, and type III medical devices. Further, it is involved in the finance leasing and factoring business; wholesale of type I medical devices, surgical devices, and other disposal medical products; provision of asset management, enterprise consulting, enterprise management advisory services, as well as logistics and storage services, as well as export its products. The company offers its products under the Jierui, Wego Ortho, Yahua, Bangde, and Hai Xing brands. It serves hospitals, blood stations, and other medical units; and distributors. The company was incorporated in 2000 and is based in Weihai, the People's Republic of China.

Full SHWGY Calculator →

MAINBDC

Main Street Capital Corporation is a business development company specializes in equity capital to lower middle market companies. The firm specializing in recapitalizations, management buyouts, refinancing, family estate planning, management buyouts, refinancing, industry consolidation, mature, later stage emerging growth. The firm also provides debt capital to middle market companies for acquisitions, management buyouts, growth financings, recapitalizations and refinancing. The firm seeks to partner with entrepreneurs, business owners and management teams and generally provides one stop financing alternatives within its lower middle market portfolio. It prefers to invest in air freight and logistics, auto components, building products, chemicals, commercial services, computers, construction and engineering, consumer finance, consumer services, electronic equipment, energy equipment and services, financial services, health care equipment, health care providers, hotels, restaurants, and leisure, internet software and services, IT Services, machinery, oil, gas and consumable fuels, paper and forest products, professional and industrial services, road and rail, software, specialty retail, telecommunication, consumer discretionary, energy, materials, technology, and transportation. The firm typically invests in lower middle market companies generally with annual revenues between $5 million and $300 million. It prefers to invest in ranging between $2 million and $75 million in equity investment and enterprise value in ranging between $3 million and $20 million. The firm typically prefers to invest in the range of $5 million and $50 million per transaction in debt investment value and in the range of $1 million and $20 million in annual EBITDA. The firm's middle market debt investments are made in businesses that are generally larger in size than its lower middle market portfolio companies. It takes 5 percent minority and up to 50 percent majority equity investments. Main Street Capital Corporation was founded in 2007 and is based in Houston, Texas with an additional office in Chojnów, Poland.

Full MAIN Calculator →
📬

Get this SHWGY vs MAIN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SHWGY vs SCHDSHWGY vs JEPISHWGY vs OSHWGY vs KOSHWGY vs ARCCSHWGY vs HTGCSHWGY vs GBDCSHWGY vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.